PCVX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PC

Mkt Cap

$10.01B

Volume

2.62M

Next Earnings

November 3rd

Loading chart

PC

PCVXVaxcyte, Inc. Common Stock

PCVX

Pay with—

Available Balance0.00

PC

Mkt Cap

$10.27B

Volume

2.62M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetVaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.Zacks Investment Research · Oct 14, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesVaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026.GlobeNewswire Inc. · Oct 7, 2026

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.Zacks Investment Research · Oct 6, 2026

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields SurgeThe Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.The Motley Fool · Oct 5, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteFour biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.Zacks Investment Research · Sep 23, 2026

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the FirmVaxcyte CEO Grant Pickering sold 6,289 shares (~$384,900) to cover tax withholding on vesting restricted stock units, retaining 447,000 direct shares. The clinical-stage biotech company, up 95% over the past year, is awaiting pivotal Phase 3 trial data for VAX-31 in Q4 2026. With $2.5 billion in cash but burning $284.3 million quarterly, the company's future hinges on successful trial results.The Motley Fool · Sep 8, 2026

Pfizer Expands Pneumococcal Vaccine Push With New ProgramsPfizer reported positive Phase 2 data for its 25-valent pneumococcal conjugate vaccine candidate (25vPnC), showing 8.8 to 15 times higher immune responses against serotype 3 compared to PREVNAR 20. The company is advancing to a pivotal Phase 3 pediatric program with up to 2,400 participants and plans to develop a 35-valent adult vaccine candidate entering clinical development by end of 2026.Benzinga · May 20, 2026

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateVaxcyte announced publication of positive Phase 1/2 clinical trial results for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in The Lancet Infectious Diseases. The vaccine demonstrated robust immune responses across all 31 serotypes and a safety profile similar to Prevnar 20. Based on these results, VAX-31 has advanced into Phase 3 clinical trials (OPUS program) with topline data expected in Q4 2026. VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease in U.S. adults aged 50 and older.GlobeNewswire Inc. · Mar 18, 2026

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesVaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of common stock at $50 per share, including the full exercise of underwriters' option for 1,650,000 additional shares. The funds will support the company's clinical-stage vaccine development programs.Benzinga · Feb 2, 2026

Vaxcyte Announces Pricing of $550 Million Public OfferingVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, announced the pricing of an underwritten public offering of 11 million shares at $50 per share, generating $550 million in gross proceeds. The offering is expected to close on February 2, 2026. The company is developing VAX-31, a 31-valent pneumococcal conjugate vaccine candidate in Phase 3 adult and Phase 2 infant clinical programs, along with other vaccine candidates in its pipeline.GlobeNewswire Inc. · Jan 30, 2026

to start trading

PC

PCVXVaxcyte, Inc. Common Stock

PCVX

Pay with—

Available Balance0.00

Your PositionYou don't own any PCVX yet.

Related Tickers

Earnings